Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated September 11, 2025, details the results of Phio Pharmaceuticals Corp.'s 2025 Annual Meeting of Stockholders. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol PHIO.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
At the Annual Meeting, stockholders approved several key proposals:
- Director Elections: All six nominees (Robert J. Bitterman, Patricia A. Bradford, David H. Deming, Robert L. Ferrara, Jonathan E. Freeman, and Curtis A. Lockshin) were elected to serve until the 2026 Annual Meeting.
- Auditor Ratification: Grant Thornton, LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025.
- Compensation Plan Amendment: Stockholders approved an amendment to the 2020 Long Term Incentive Plan, increasing the number of shares available for issuance by 950,000 to a total of 1,023,017 shares.
- Say on Pay: The compensation of named executive officers was approved via a non-binding advisory vote.
- Say on Frequency: Stockholders voted to hold future advisory votes on executive compensation every three years.
Voting Statistics: There were 4,798,154 shares issued and outstanding as of the July 18, 2025 record date. A total of 2,374,235 shares were present at the meeting. Broker non-votes totaled 1,828,465 shares for the director elections and the incentive plan amendment.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, specific risks, or contingencies beyond the standard incorporation of the amended incentive plan text.
Investor Verification Checklist
- Verify the impact of the 950,000 share increase in the 2020 Long Term Incentive Plan on potential future dilution.
- Review the full text of the amended 2020 Plan filed as Exhibit 10.1 for specific terms and vesting schedules.
- Confirm the re-election of the current board composition and their tenure through 2026.
- Note the significant number of broker non-votes (1,828,465) which did not affect the outcome of the director elections but indicates a large portion of shares held in street name.